The study publicshed in the New England Journal of Medicine titled “Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy” investigates the long-term safety of the gene therapy elivaldogene autotemcel (eli-cel) in patients with cerebral adrenoleukodystrophy (CALD). The therapy modifies patients’ own blood-forming stem cells to include a functional gene to manage CALD. However, 7 of 67 patients developed hematologic cancers, like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), which may be connected to where the viral vector inserts the gene in the DNA. These findings underscore both the promise and challenges of gene therapy for CALD.
Study Goals and Methods
The study evaluated the genetic factors and safety of eli-cel, focusing on understanding if gene insertion might lead to cancers. Patients with CALD received eli-cel, and researchers conducted genetic analyses on their blood and bone marrow to detect any clonal expansions (groups of cells with similar genetic mutations) that might indicate cancer. They monitored 67 patients, gathering data from two primary studies, ALD-102 and ALD-104, and an additional long-term follow-up study, LTF-304.
Key Results
- Hematologic Cancer Occurrence: Seven patients developed hematologic cancers between 14 to 92 months after eli-cel treatment, including cases of MDS and AML.
- Oncogene Involvement: Six of these seven patients had abnormal cell growth with gene insertions near known cancer-related genes (oncogenes), especially MECOM and PRDM16. Many also had additional somatic mutations in genes commonly linked to cancer, such as KRAS and WT1.
- Post-Diagnosis Management: Five patients underwent stem-cell transplants to treat their cancer. While four remain free from MDS after transplantation, one died due to complications likely tied to treatment. The remaining patients are under observation, with one awaiting stem-cell transplant.
Detailed Findings on Genetic Mechanisms
The study highlights that the gene therapy’s viral vector may contribute to cancer risk if it integrates into oncogenes. Specifically, gene insertions in the MECOM and PRDM16 genes in several patients suggest that certain insertion sites can increase the risk of cell abnormalities and cancer development. This phenomenon, known as “insertional oncogenesis,” involves the viral vector disrupting normal cell growth regulation, leading to clonal expansions.
Broader Implications and Next Steps
While eli-cel shows promise for stabilizing CALD, this research emphasizes the need for long-term monitoring due to the potential for cancer risks. Although lentiviral vectors, like Lenti-D used in eli-cel, are designed to minimize risks compared to earlier retroviral methods, their use near certain genes may still pose risks. The study’s findings call for improved gene delivery technologies that avoid high-risk insertion sites and safer conditioning regimens to reduce post-therapy complications.
In conclusion, eli-cel represents a significant advancement in CALD treatment, offering a non-donor-based therapy option that reduces immune rejection risks. However, understanding and mitigating its long-term risks is essential to improve patient safety.
For more detailed information, you can access the full study here.
*The United Leukodystrophy Foundation is not liable for any inaccuracies or gaps in these overviews , which are offered “as is” without assurances on completeness, accuracy, or timeliness. For verification or detailed information, please consult the original articles directly.
As a leukodystrophy related nonprofit, the ULF provides awareness to scientific literature. Inclusion on our website does not imply endorsement of, or agreement with, the contents by the ULF.